

- **Full Name:** Rodrigo Dienstmann
  - **Current Position & Affiliation:** Group Leader, Oncology Data Science, Barcelona, Spain  
Medical Director, Oncoclínicas Precision Medicine, São Paulo, Brazil
  - **Country:** Spain, Brazil
- 

- **Educational Background:**

- Medicine

- Feb 1996 – Dic 2001
- Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

- Residency

- Jan 2002 – Dic 2003
- Internal Medicine, Hospital de Clínicas de Porto Alegre, Brazil

- Fellowship

- Jan 2004 – Jan 2006
- Clinical Oncology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

- Post-Graduation

- Feb 2006 – Dic 2009
- Clinical Research in Oncology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil
- Feb 2010 – Dec 2012
- Molecular Therapeutics Research Unit, Vall d'Hebron Institute of Oncology, Spain
- Jan 2013 – Sep 2013
- Molecular Pathology Lab, Massachusetts General Hospital, Boston, USA
- Oct 2013 – Feb 2015
- Computational Oncology, Sage Bionetworks, Seattle, USA
- Apr 2017 – Jun 2017
- Management in the healthcare section Training Program IESE Business School, Madrid, Spain

- Master's degree

- Jan 2018 – Jun 2019
- Executive master's in business administration (MBA) ESADE Business School, Barcelona, Spain

- **Professional Experience:**

- Current Positions

- 2020 – present:
- Medical Director, Oncoclínicas Precision Medicine and Big Data, Brazil
- 2015 – present:
- Group Leader, Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Spain

• **Professional Organizations:**

- |  |                 |
|--|-----------------|
| - American Society of Clinical Oncology (ASCO)     | since June 2006 |
| - American Association for Cancer Research (AACR)  | since June 2006 |
| - European Society for Medical Oncology (ESMO)     | since July 2009 |
| - Sociedade Brasileira de Oncologia Clínica (SBOC) | since Jan 2010  |

Editor-in-Chief

- ESMO Real World Data and Digital Oncology

• **Main Scientific Publications:**

1. The consensus molecular subtypes of colorectal cancer  
Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend S, Laurent-Puig P, Medema J, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. *Nat Med* 2015;21(11):1350-6
2. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)  
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Puztai L. *Ann Oncol* 2018; 29(9):1895-1902
3. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal  
Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J. *Nat Med* 2020;26(7):992-994
4. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group  
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. *Ann Oncol* 2020;S0923-7534(20):39971-3
5. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal  
Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X,

Chavarria E; Cancer Core Europe consortium, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J. *Nat Med* 2020;26(7):992-994.